Merrem I.V. Shortage Due To Increased Regional Demand, AstraZeneca Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s website states the antibiotic shortage stems from “manufacturing delays due to bulk drug supply shortages.” The company does not plan to ration shipments to U.S. regions that are not experiencing increased demand.